UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of earliest event reported) | November 13, 2006 |
Targeted Genetics Corporation |
| (Exact name of registrant as specified in its charter) |
Washington | 0-23930 | 91-1549568 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
1100 Olive Way, Suite 100, Seattle, Washington | 98101 |
| (Address of principal executive offices) | (Zip Code) |
| Registrant's telephone number, including area code | (206) 623-7612 |
Not Applicable |
| (Former name or former address if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On November 13, 2006, Targeted Genetics Corporation announced the presentation of the interim data from its ongoing Phase I/II trial of tgAAC94 in patients with inflammatory arthritis. A copy of Targeted Genetics’ press release announcing the presentation of the interim data and describing the interim data is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
Exhibits.
99.1 Press Release of Targeted Genetics Corporation dated November 13, 2006
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | |
| | Targeted Genetics Corporation |
|
|
|
| By: | /s/ David J. Poston |
| |
David J. Poston Vice President Finance and Chief Financial Officer |
| | |
Dated: November 15, 2006
INDEX TO EXHIBITS
Exhibit Number | | Description |
| 99.1 | | Press Release of Targeted Genetics Corporation dated November 13, 2006 |
